In Section A, contributors will receive unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing routine. Additional individuals are going to be enrolled in the determined monotherapy dosign program. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 is going to be presented as "increase-on" therapy. https://alfredm777alw9.bligblogging.com/profile